Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312067180> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4312067180 endingPage "443" @default.
- W4312067180 startingPage "437" @default.
- W4312067180 abstract "Background and Aims: The sofosbuvir (SOF) / velpatasvir (VEL) / voxilaprevir (VOX) combination has been evaluated in more than 800 patients enrolled in phase II and phase III studies, where it demonstrated excellent safety and efficacy, achieving overall sustained viral response (SVR) rates of more than 95%. We aimed to assess the efficacy and safety of SOF/VEL/VOX in a real-world study, including patients previously treated for genotype 1b hepatitis C virus (HCV) infection that did not obtain a sustained viral response with previous direct‐acting antivirals (DAAs) therapy.
 Methods: In Romania, through a nationwide government-funded program in 2019-2020, 213 patients with chronic hepatitis C non-responders to previous DAAs therapy, received treatment with SOF/VEL/ VOX 400/100/100 mg/day for 12 weeks. We performed a retrospective longitudinal study that included 143 individuals who were treated in Bucharest, Iași, Craiova and Constanța clinics, all with genotype 1b HCV infection. Efficacy was assessed by the percentage of patients achieving SVR 12 weeks post-treatment (SVR12). Serious adverse events (SAE) were registered.
 Results: Our cohort comprised 53% males with a median age of 60 years (27÷77); 47% were pre-treated with ombitasvir/paritaprevir/ritonavir+dasabuvir ± ribavirin, 40% with ledipasvir/SOF, 13% with elbasvir/ grazoprevir. 42% of patients associated co-morbidities, 45% had compensated liver cirrhosis, 2% had treated hepatocellular carcinoma (HCC) and 1% had hepatitis B virus co-infection. SVR by intention to treat was reported in 139/143 (97.2%) and per protocol in 141/143 (98.6%). No predictive factors for SVR were identified. Rate of liver decompensation in patients with cirrhosis was 6% and was statistically associated in multivariate analysis with Child-Pugh score (p<0.01) and with severe steatosis (p=0.004). Occurrence of new HCC was reported in 3.6% of all patients with cirrhosis and was associated with poor liver function [higher Child-Pugh score (p=0.001) and low albumin levels (p=0.02)]. Serious adverse events related to therapy were reported in 1/143(0.7%).
 Conclusions: SOF/VEL/VOX was highly efficient in our population of patients with a 97.2% SVR. Liver decompensation occurred in 6% of cirrhotic patients at SVR, related to hepatic dysfunction." @default.
- W4312067180 created "2023-01-04" @default.
- W4312067180 creator A5023716466 @default.
- W4312067180 creator A5026802895 @default.
- W4312067180 creator A5027223109 @default.
- W4312067180 creator A5034382418 @default.
- W4312067180 creator A5039504054 @default.
- W4312067180 creator A5045177087 @default.
- W4312067180 creator A5045581372 @default.
- W4312067180 creator A5046474371 @default.
- W4312067180 creator A5050685536 @default.
- W4312067180 creator A5054322001 @default.
- W4312067180 creator A5062174706 @default.
- W4312067180 creator A5070930784 @default.
- W4312067180 creator A5078983980 @default.
- W4312067180 date "2022-12-17" @default.
- W4312067180 modified "2023-10-18" @default.
- W4312067180 title "Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy" @default.
- W4312067180 doi "https://doi.org/10.15403/jgld-4472" @default.
- W4312067180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36535062" @default.
- W4312067180 hasPublicationYear "2022" @default.
- W4312067180 type Work @default.
- W4312067180 citedByCount "1" @default.
- W4312067180 countsByYear W43120671802023 @default.
- W4312067180 crossrefType "journal-article" @default.
- W4312067180 hasAuthorship W4312067180A5023716466 @default.
- W4312067180 hasAuthorship W4312067180A5026802895 @default.
- W4312067180 hasAuthorship W4312067180A5027223109 @default.
- W4312067180 hasAuthorship W4312067180A5034382418 @default.
- W4312067180 hasAuthorship W4312067180A5039504054 @default.
- W4312067180 hasAuthorship W4312067180A5045177087 @default.
- W4312067180 hasAuthorship W4312067180A5045581372 @default.
- W4312067180 hasAuthorship W4312067180A5046474371 @default.
- W4312067180 hasAuthorship W4312067180A5050685536 @default.
- W4312067180 hasAuthorship W4312067180A5054322001 @default.
- W4312067180 hasAuthorship W4312067180A5062174706 @default.
- W4312067180 hasAuthorship W4312067180A5070930784 @default.
- W4312067180 hasAuthorship W4312067180A5078983980 @default.
- W4312067180 hasBestOaLocation W43120671801 @default.
- W4312067180 hasConcept C126322002 @default.
- W4312067180 hasConcept C159047783 @default.
- W4312067180 hasConcept C197934379 @default.
- W4312067180 hasConcept C2522874641 @default.
- W4312067180 hasConcept C2775999097 @default.
- W4312067180 hasConcept C2776408679 @default.
- W4312067180 hasConcept C2776455275 @default.
- W4312067180 hasConcept C2777100407 @default.
- W4312067180 hasConcept C2778390639 @default.
- W4312067180 hasConcept C2778785139 @default.
- W4312067180 hasConcept C2778867932 @default.
- W4312067180 hasConcept C2780040827 @default.
- W4312067180 hasConcept C71924100 @default.
- W4312067180 hasConcept C90924648 @default.
- W4312067180 hasConceptScore W4312067180C126322002 @default.
- W4312067180 hasConceptScore W4312067180C159047783 @default.
- W4312067180 hasConceptScore W4312067180C197934379 @default.
- W4312067180 hasConceptScore W4312067180C2522874641 @default.
- W4312067180 hasConceptScore W4312067180C2775999097 @default.
- W4312067180 hasConceptScore W4312067180C2776408679 @default.
- W4312067180 hasConceptScore W4312067180C2776455275 @default.
- W4312067180 hasConceptScore W4312067180C2777100407 @default.
- W4312067180 hasConceptScore W4312067180C2778390639 @default.
- W4312067180 hasConceptScore W4312067180C2778785139 @default.
- W4312067180 hasConceptScore W4312067180C2778867932 @default.
- W4312067180 hasConceptScore W4312067180C2780040827 @default.
- W4312067180 hasConceptScore W4312067180C71924100 @default.
- W4312067180 hasConceptScore W4312067180C90924648 @default.
- W4312067180 hasIssue "4" @default.
- W4312067180 hasLocation W43120671801 @default.
- W4312067180 hasLocation W43120671802 @default.
- W4312067180 hasOpenAccess W4312067180 @default.
- W4312067180 hasPrimaryLocation W43120671801 @default.
- W4312067180 hasRelatedWork W2323574296 @default.
- W4312067180 hasRelatedWork W2339494956 @default.
- W4312067180 hasRelatedWork W2506407466 @default.
- W4312067180 hasRelatedWork W2514340439 @default.
- W4312067180 hasRelatedWork W2552228682 @default.
- W4312067180 hasRelatedWork W2565807151 @default.
- W4312067180 hasRelatedWork W2587635005 @default.
- W4312067180 hasRelatedWork W2593539364 @default.
- W4312067180 hasRelatedWork W2803767567 @default.
- W4312067180 hasRelatedWork W2945229546 @default.
- W4312067180 hasVolume "31" @default.
- W4312067180 isParatext "false" @default.
- W4312067180 isRetracted "false" @default.
- W4312067180 workType "article" @default.